Home › Neuroblastoma › Maryland
Neuroblastoma clinical trials in Maryland
8 studies for Neuroblastoma are looking for participants at sites in Maryland.
Cities in Maryland
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 9, 2026 · NCT06041516Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 4 and older · All sexes · Updated Nov 5, 2026 · NCT01005654Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- and 1 more
RecruitingPhase 3
Up to age 30 · All sexes · Updated Oct 30, 2026 · NCT06172296Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 3 to 35 · All sexes · Updated Oct 21, 2026 · NCT06995872Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Oct 16, 2026 · NCT01109394Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916SPEARHEAD-3 Pediatric Study
- National Institutes of Health, Bethesda
RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.